Bausch + Lomb abandons glaucoma eye drop after phase 2 failure

Seeking Alpha··Read original
2▲0 ▼1Impact / 5
Summary · why it matters

Bausch + Lomb will discontinue development of its glaucoma eye drop BL1107 after the candidate failed to meet its primary goal in a phase 2 study. The treatment did not lead to visual function improvements after 28 days, despite showing improvement in a smaller phase 1/2a study. The company will continue to pursue the asset as a sustained-release implant for geographic atrophy, with trials for that indication expected to start in 2028.

Impact on assets 1

Health Care▼ · 1 stocks
Bausch + Lomb Corp
BLCO
▼ NegativeTechnologyrelevance

Glaucoma eye drop BL1107 failed phase 2 trial, leading to discontinuation of that program.

© 2026 MarketIVNews